Hygienic ACTC minimizes trauma to cancer patients
Mr. Zhang, female, retired in 2015. Thinking of working hard for decades, now that his grandson is in middle school and does not need to be picked up, he made a detailed travel plan and went on a trip. On the way to travel, Zhang found a lump in his chest. He didn't care about it at first. Later, he found that the lump had not subsided, so he went to the hospital for examination. After being diagnosed with stage I breast cancer, he underwent surgical resection under the doctor's advice. After half a year of recovery, the results of the reexamination at the end of the year made him collapse, and a tumor as large as before the operation grew again in the right breast.
Faced with such a situation, Zhang was entangled in whether he needed another operation? Can he survive two operations within a year? Whether to puncture the tissue? How to determine the targeted drug? Many tumor patients have also faced Zhang Confused, I have cancer. When taking targeted drug or chemotherapy drug treatment, the acquisition of tissue samples has become a key, or even a difficult problem, and the process of obtaining tissue samples is invasive. Through non-invasive detection of circulating tumor cells (Circulating Tumor Cells, CTCs), the product assists in the diagnosis of tumors and minimizes the trauma of tumor patients.
During the development of solid tumors, tumor cells shed from the primary tumor enter the peripheral blood circulation, and these cells are called circulating tumor cells, which are an important source of tumor metastasis. The vast majority of tumor cells shed directly from the primary tumor exhibit the characteristics of epidermal cells, but such cells lose certain epithelial characteristics (including morphology, surface antigens, etc.) in order to gain motility and invasiveness in the peripheral blood circulation. , gene expression, etc.) and obtain some properties of mesenchymal cells. Traditional products for detecting CTCs only detect CTCs from epithelial origin, and will miss CTCs from mesenchyme, and the sensitivity is not high.
ACTC (Accurate Circulating Tumor Cells) technology is an international technology jointly researched by Chinese and American scientists for the detection of peripheral blood CTCs. It uses negative + positive enrichment technology to accurately identify and capture CTCs in blood. Firstly, using the difference between the density of CTCs and other components in the blood, 99.9% of the blood cells (including red blood cells, white blood cells, platelets, etc.) in the whole blood are removed through the cell density gradient centrifugation fluid of the patented technology of Hegeli, so as to realize the enrichment of CTCs. Then, using the flow cytometry platform, fluorescently labeled epithelial-derived antibodies, mesenchymal-derived antibodies and tissue-specific antibodies were used to jointly identify CTCs, not only epithelial-derived and mesenchymal-derived tumor cells, but also EMT-transformed. mesenchymal tumor cells. At the same time, the source of the primary tissue of CTCs can be traced back, assisting clinicians to determine the primary location of tumor tissue, and greatly improving the sensitivity and specificity of CTCs detection.
Haijili ACTC products can solve 5 major clinical needs: ①Auxiliary diagnosis of suspected tumor cases; ②Monitoring the effect of surgery, radiotherapy/chemotherapy, and biological treatment; ③It can monitor the risk of tumor metastasis and recurrence; ④It can monitor tumor drug resistance The occurrence of tumor; ⑤ tumor prognosis can be assessed.
In order to solve Zhang's confusion, we used an EDTA anticoagulation tube, collected 5ml of peripheral blood, and tested it with ACTC products. The test results are as follows:
The test results showed that the number of CTCs in this Zhang was significantly higher than that of the normal population, and the interstitial and mixed (interstitial + epidermal double positive) CTC cells accounted for 9/11 of the number of CTCs in the middle, showing a relatively obvious epidermal to mesenchymal transition. cells, indicating that Zhang
The tumor has a high degree of malignancy, and further diagnosis is recommended.
Zhang's molecular test result was ER-PR-HER2-, which is a triple-negative breast cancer patient, indicating that the patient's breast cancer has a high degree of malignancy. Zhang underwent surgical resection, and it is recommended to use ACTC products for regular efficacy monitoring.
The ACTC product independently developed by Haijili can detect the number of circulating tumor cells without tissue samples and only needs 5ml of peripheral blood. It is an ideal clinical tumor detection technology and has the characteristics of non-invasive, accurate, early and real-time dynamic monitoring; Traceability and efficacy evaluation have significant advantages; they have good monitoring effects for lung cancer, liver cancer and breast cancer. Some of these products have been approved by CFDA, and colleagues are welcome to inquire.